The Rewired
Brain

Section I

The Second Confirmation

On February 17, 2026, Compass Pathways announced results that no one in psychiatry had expected to see twice so cleanly: COMP360, its synthetic psilocybin compound, had met its primary endpoint in a second independent Phase 3 clinical trial for treatment-resistant depression. The first result, from the COMP001 trial reported in 2022, could conceivably have been ascribed to statistical fortune or the peculiarities of a single trial design. The second result, from the COMP006 trial — an independent experiment involving hundreds of patients, the same 25-milligram dose protocol, and the same outcome measure — was something different. Two Phase 3 trials. Both positive. Effects onset as early as the day after treatment. Response lasting at least 26 weeks from one or two sessions. That is what the FDA calls a drug.

The COMP006 results reported a statistically significant reduction in depressive symptom severity at week six compared with a 1-milligram active control dose — a dose low enough to serve as a practical placebo (participants experience minimal perceptual effects, so the comparison is as close to blinded as psilocybin trials can achieve). Patients who responded to a 25-milligram session maintained improvements well beyond the six-week primary endpoint. For a condition — treatment-resistant depression, or TRD — in which patients have already failed two or more adequate courses of antidepressant medication, and for which no FDA-approved treatment currently exists that acts faster than weeks, these results represent a clinical advance of genuine magnitude.

The treatment is not a pill taken at home each morning. It is a session. Patients come to a clinical setting, are given a single 25-milligram oral dose of synthetic psilocybin, and remain in the room — accompanied by trained therapists — for six to eight hours while the drug takes effect and the experience unfolds. One or two sessions constitute the full treatment course. The therapeutic effects that follow last for months. For psychiatry, which has operated for decades on the model of daily medications that modulate neurochemistry indefinitely, this is a structural inversion. Understanding why it works requires looking inside the brain.

Section II

The Default Mode Network and the Architecture of Rumination

Depression, at its neural core, is a disorder of stuck patterns. The brain of a person with severe depression is not simply sad — it is structurally constrained in ways that modern neuroimaging has only recently made visible. The mechanism through which psilocybin disrupts those constraints is one of the most striking discoveries in contemporary neuroscience.

The default mode network (DMN) is a set of brain regions — centred on the medial prefrontal cortex at the front of the brain, the posterior cingulate cortex at the back, and the angular gyrus on both sides — that activates when the mind is at rest and not engaged with the external world. It is the network of self-referential thought: the part of the brain doing the mental chatter when you are not focused on a task. Evolutionarily, it likely serves functions including planning, social cognition, and narrative self-construction. In healthy people, the DMN activates and deactivates fluidly, shifting as attention moves between inward reflection and outward engagement.

In depression, the DMN appears to become pathologically hyperactive and rigidly self-reinforcing. Rather than cycling normally, it loops — generating the relentless, self-critical rumination that characterises the disorder. Functional MRI studies show that severely depressed patients' DMNs are abnormally strongly connected, as if the network has become stuck in a fixed gear. The brain cannot easily shift out of the ruminative loop into other modes of processing. Conventional antidepressants — SSRIs, SNRIs — modulate the serotonergic system broadly but do not directly address this large-scale network architecture.

The physical substrate of this rewiring involves structural neuroplasticity — literal changes in the brain's anatomy. Studies in animals and, increasingly, in humans have found that psilocybin promotes the growth of new dendritic spines — the tiny protrusions on neurons through which they receive synaptic connections — within 24 hours of a single dose, and that these new spines are maintained for weeks. The brain is not merely temporarily altered during the drug experience; it is physically remodelled. The molecule that mediates much of this effect is BDNF — brain-derived neurotrophic factor, a protein that supports neuronal survival and the growth of new connections — which psilocybin upregulates substantially. The drug, in effect, opens a window of heightened neuroplasticity in which the brain is more capable than usual of forming new patterns, and in which the therapeutic conversation happening in the room with the patient may be literally shaping the new architecture being built.

This is why the session matters. The neuroplasticity window opened by psilocybin is time-limited — perhaps 24 to 72 hours at maximum intensity, with some elevated plasticity for longer. What happens during and immediately after that window shapes what the brain's new connections encode. The quality of the therapeutic environment, the preparatory work done before the session, and the integration work done after it are not merely adjuncts to the pharmacological treatment. They are, according to the mechanistic model, part of the mechanism itself.

Section III

Two Drugs, Two Paths, One Setback

The psychedelic medicine pipeline is not monolithic. Two compounds have reached late-stage FDA trials — psilocybin and MDMA — and their regulatory trajectories have diverged sharply, in ways that illuminate both the promise and the difficulty of this class of therapeutics.

MDMA-assisted therapy for post-traumatic stress disorder was the first to reach Phase 3, developed by the Multidisciplinary Association for Psychedelic Studies (MAPS) through its commercial arm Lykos Therapeutics. The Phase 3 results were striking: in one trial, nearly 70 percent of participants no longer met the diagnostic criteria for PTSD after treatment. In August 2024, the FDA issued a complete response letter to Lykos — a formal rejection, requesting an additional clinical trial before approval. The reasons cited included concerns about trial integrity (blinding is difficult when participants can tell whether they received MDMA or placebo), potential misconduct in some trial sites, and insufficient data on abuse liability and cardiac safety. The decision was a significant setback for the field, though not a scientific refutation of MDMA's therapeutic effects. The FDA's concerns were methodological, not mechanistic. Other MDMA researchers have taken note and are designing follow-on trials specifically to address those concerns.

The state-level landscape has moved in parallel with the federal regulatory path. Oregon's Measure 109, passed in 2020, created a regulated framework for licensed psilocybin service centres — not medical treatment, but supervised adult access to psilocybin facilitation. Service centres began operating in Oregon in 2023. Colorado passed Proposition 122 in 2022, creating a similar framework. These state programmes do not require FDA approval and exist in a legally distinct space from the medical approval pathway. They are, in effect, running a parallel natural experiment in access under regulated conditions.

The MDMA setback clarified something important for everyone in the field: the FDA will not approve a psychedelic therapy on the strength of dramatic clinical results alone if methodological questions remain unresolved. The bar is not lower for this class of compounds because the effects are unusual or the need is great. If anything, the bar is higher, because blinding failures and the intrinsic subjectivity of the therapeutic experience create audit challenges that conventional drug trials do not face. Compass Pathways has designed its programme specifically to withstand that scrutiny. Whether the FDA agrees will be known in 2027.

Section IV

The Medicine of Sessions, Not Pills

If COMP360 receives FDA approval — which, pending a successful NDA review in 2026-27, is now a genuine near-term prospect — the clinical infrastructure that would need to exist to deliver it does not yet exist at scale. This is the underappreciated challenge of psychedelic medicine: it is not a tablet that can be prescribed, dispensed, and taken at home. It is a supervised therapeutic intervention requiring trained facilitators, appropriate clinical space, six to eight hours of patient time, and a structured programme of preparation and integration work around the acute session.

The number of therapists and facilitators currently trained in psilocybin-assisted therapy in the United States is a small fraction of what would be needed for even modest clinical adoption. Training programmes have been scaling — through institutions including the California Institute of Integral Studies, the Integrative Psychiatry Institute, and programmes associated with Johns Hopkins, NYU, and UCSF — but the pipeline is measured in hundreds of practitioners, not thousands. A treatment for major depression with an estimated 17 million Americans affected and a treatment-resistant subpopulation of perhaps 4 million would require a scale of trained providers that does not exist.

The important distinction that often collapses in public discussion is between FDA medical approval and decriminalisation. They are different instruments with different purposes. FDA approval means a specific drug, manufactured to a specific standard, administered in a specific therapeutic protocol, can be legally prescribed for a specific indication. Decriminalisation means that personal possession and use are no longer criminal offences, but creates no framework for clinical access or insurance coverage. Oregon and Colorado's frameworks sit between the two — regulated access outside the medical system. All three pathways are now advancing simultaneously. They serve overlapping but distinct populations.

What the February 17, 2026 COMP360 results confirmed is that psilocybin-assisted therapy for treatment-resistant depression is not a promising experimental approach anymore. It is a treatment that has now met FDA's primary threshold twice. The patients who responded — people who had failed, in some cases, a decade of conventional antidepressant regimens, who had not been able to leave their homes, who described their pre-treatment inner life in terms that should stop any reader cold — had experiences that produced changes lasting at least six months from a single afternoon. The brain does rewire. The question that remains is not whether the science supports this therapy. The question is whether the healthcare system can build what is needed to deliver it to the people waiting.